SEARCH

SEARCH BY CITATION

References

  • 1
    Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol 1984: 97: 357365.
  • 2
    Haim M. Epidemiology of retinitis pigmentosa in Denmark. Acta Ophthalmol Scand 2002: 233: 134.
  • 3
    Burton H, Alberg C, Moore AT. Genetics in ophthalmology: equity in service provision? J Public Health (Oxf) 2010: 32: 259266.
  • 4
    Hamblion EL, Moore AT, Rahi JS. Incidence and patterns of detection and management of childhood-onset hereditary retinal disorders in the UK. Br J Ophthalmol 2012: 96: 360365.
  • 5
    Sutherland JE, Day MA. Genetic counseling and genetic testing in ophthalmology. Curr Opin Ophthalmol 2009: 20: 343350.
  • 6
    Morad Y, Sutherland J, DaSilva L et al. Ocular Genetics Program: multidisciplinary care of patients with ocular genetic eye disease. Can J Ophthalmol 2007: 42: 734738.
  • 7
    Stroh E. Taking the family history in genetic disease: a guide for ophthalmologists. Curr Opin Ophthalmol 2011: 22: 340346.
  • 8
    Greenberg G. Beyond the blindfold: my life with retinitis pigmentosa. Clin Dermatol 2005: 23: 640642; discussion 642–643.
  • 9
    Cohen SA, Gustafson SL, Marvin ML et al. Report from the National Society of Genetic Counselors service delivery model task force: a proposal to define models, components, and modes of referral. J Genet Couns 2012: 21: 645651.
  • 10
    Smerecnik CM, Mesters I, Verweij E, de Vries NK, de Vries H. A systematic review of the impact of genetic counseling on risk perception accuracy. J Genet Couns 2009: 18: 217228.
  • 11
    Branham K, Othman M, Brumm M et al. Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci 2012: 53: 82328237.
  • 12
    Churchill JD, Bowne SJ, Sullivan LS et al. Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2013: 54: 14111416.
  • 13
    Neveling K, Collin RW, Gilissen C et al. Next-generation genetic testing for retinitis pigmentosa. Hum Mutat 2012: 33: 963972.
  • 14
    Daiger SP, Sullivan LS, Bowne SJ. Genes and mutations causing retinitis pigmentosa. Clin Genet 2013 (in press).
  • 15
    Boon CJ, van Schooneveld MJ, den Hollander AI et al. Mutations in the peripherin/RDS gene are an important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. Br J Ophthalmol 2007: 91: 15041511.
  • 16
    Renner AB, Fiebig BS, Weber BH et al. Phenotypic variability and long-term follow-up of patients with known and novel PRPH2/RDS gene mutations. Am J Ophthalmol 2009: 147: 518530 e511.
  • 17
    Weleber RG, Carr RE, Murphey WH, Sheffield VC, Stone EM. Phenotypic variation including retinitis pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of codon 153 or 154 of the peripherin/RDS gene. Arch Ophthalmol 1993: 111: 15311542.
  • 18
    Koenekoop RK, Lopez I, den Hollander AI, Allikmets R, Cremers FP. Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin Experiment Ophthalmol 2007: 35: 473485.
  • 19
    Bennett J, Ashtari M, Wellman J et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012: 4: 120ra115.
  • 20
    Simonelli F, Maguire AM, Testa F et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010: 18: 643650.
  • 21
    Jacobson SG, Acland GM, Aguirre GD et al. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006: 13: 10741084.
  • 22
    Lopes VS, Boye SE, Louie CM et al. Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther 2013. Epub ahead of print; doi:10.1038/gt.2013.3.
  • 23
    Beltran WA, Cideciyan AV, Lewin AS et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA 2012: 109: 21322137.
  • 24
    Janssen A, Min SH, Molday LL et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 2008: 16: 10101017.
  • 25
    Kjellstrom S, Bush RA, Zeng Y, Takaha Y, Sieving PA. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 2007: 48: 38373845.
  • 26
    Park TK, Wu Z, Kjellstrom S et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009: 16: 916926.
  • 27
    Michalakis S, Muhlfriedel R, Tanimoto N et al. Restoration of cone vision in the CNGA3−/− mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 2010: 18: 20572063.
  • 28
    Komaromy AM, Rowlan JS, Corr AT et al. Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther 2013. Epub ahead of print; doi:10.1038/mt.2013.50.
  • 29
    Carvalho LS, Xu J, Pearson RA et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 2011: 20: 31613175.
  • 30
    Radu RA, Yuan Q, Hu J et al. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci 2008: 49: 38213829.
  • 31
    Organisciak DT, Vaughan DK. Retinal light damage: mechanisms and protection. Prog Retin Eye Res 2010: 29: 113134.
  • 32
    Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res 2012: 31: 195212.
  • 33
    Stone EM, Aldave AJ, Drack AV et al. Recommendations for genetic testing of inherited eye diseases: report of the American Academy of Ophthalmology task force on genetic testing. Ophthalmology 2012: 119: 24082410.
  • 34
    Hahm BJ, Shin YW, Shim EJ et al. Depression and the vision-related quality of life in patients with retinitis pigmentosa. Br J Ophthalmol 2008: 92: 650654.
  • 35
    Herse P. Retinitis pigmentosa: visual function and multidisciplinary management. Clin Exp Optom 2005: 88: 335350.
  • 36
    Szlyk JP, Fishman GA, Grover S, Revelins BI, Derlacki DJ. Difficulty in performing everyday activities in patients with juvenile macular dystrophies: comparison with patients with retinitis pigmentosa. Br J Ophthalmol 1998: 82: 13721376.
  • 37
    Nyman SR, Dibb B, Victor CR, Gosney MA. Emotional well-being and adjustment to vision loss in later life: a meta-synthesis of qualitative studies. Disabil Rehabil 2012: 34: 971981.
  • 38
    Bittner AK, Edwards L, George M. Coping strategies to manage stress related to vision loss and fluctuations in retinitis pigmentosa. Optometry 2010: 81: 461468.
  • 39
    Kiser AK, Mladenovich D, Eshraghi F, Bourdeau D, Dagnelie G. Reliability and consistency of visual acuity and contrast sensitivity measures in advanced eye disease. Optom Vis Sci 2005: 82: 946954.
  • 40
    Turano KA, Geruschat DR, Stahl JW. Mental effort required for walking: effects of retinitis pigmentosa. Optom Vis Sci 1998: 75: 879886.
  • 41
    Jangra D, Ganesh A, Thackray R et al. Psychosocial adjustment to visual loss in patients with retinitis pigmentosa. Ophthalmic Genet 2007: 28: 2530.
  • 42
    CNIB. The status of Canadian youth who are blind or visually impaired: a study of lifestyles, quality of life, and employment 2004.Retrieved, from the CNIB website: http://www.cnib.ca/en/about/Publications/research/Pages/youth-study-executive-summary.aspx. Accessed on May 2, 2013.
  • 43
    Grover S, Fishman GA, Anderson RJ et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology 1999: 106: 17801785.
  • 44
    Zanko A, Fox M. Actively engaging with patients in decision making. In: Leroy BS, McCarthy Veach P, Bartels DM, eds. Genetic counseling practice: advanced concepts and skills. Hoboken, NJ: John Wiley & Sons, Inc., 2010.
  • 45
    Baty BJ. Risk communication and decision making. In: Uhlmann WR, Schuette JL, Yashar BM, eds. A guide to genetic counseling. Hoboken, NJ: John Wiley & Sons, Inc., 2009.
  • 46
    Hayeems RZ, Geller G, Finkelstein D, Faden RR. How patients experience progressive loss of visual function: a model of adjustment using qualitative methods. Br J Ophthalmol 2005: 89: 615620.